Pharma Pioneer

NUV-1511 Phase 1/2 Trial Begins with First Patient Dosing for Advanced Tumor Treatment

19 May 2024
2 min read

Nuvation Bio, a biopharmaceutical firm focused on addressing critical needs in cancer treatment, has initiated clinical trials for its first drug-drug conjugate (DDC), NUV-1511. The Phase 1/2 study marks a pivotal moment for the company's innovative platform, which aims to develop potent cancer-fighting drugs that target cancer cells while sparing healthy tissues. David Hung, the company's CEO, emphasized the significance of this achievement for Nuvation Bio's DDC technology, which is central to the company's founding principles.
The clinical trial is designed with flexibility to explore two dosing schedules for NUV-1511, with the primary objectives of determining the optimal Phase 2 dosage and evaluating the drug's safety, pharmacokinetics, and potential clinical benefits. The study will involve patients with various types of advanced solid tumors, including those who have not responded to treatments such as Enhertu® and Trodelvy®, as well as those with specific types of breast, prostate, pancreatic, and ovarian cancers.
Nuvation Bio, established in 2018 by David Hung, is dedicated to creating novel therapeutics for challenging cancers. The company's portfolio comprises a range of oncology therapeutics, each targeting different forms of cancer. Hung, who also founded Medivation, Inc., which developed a leading prostate cancer treatment, has brought his expertise to Nuvation Bio, which maintains a presence in both New York and San Francisco.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

New Human Data Reinforces CAN10's Potential for Treating Systemic Sclerosis
Pharma Pioneer
3 min read
New Human Data Reinforces CAN10's Potential for Treating Systemic Sclerosis
19 May 2024
The company's research has discovered that the cytokines targeted by CAN10, namely IL-1, IL-33, and IL-36, are significantly elevated in the skin samples of systemic sclerosis patients.
Read →
Lantern Pharma Initiates Human Trials with AI-Driven Drug Candidate LP-284
Pharma Pioneer
3 min read
Lantern Pharma Initiates Human Trials with AI-Driven Drug Candidate LP-284
19 May 2024
Lantern Pharma's AI-driven drug candidate, LP-284, has entered a Phase 1 clinical trial, marking a significant step in the fight against cancer.
Read →
Encouraging Results on Briquilimab as Conditioning Therapy for Fanconi Anemia Patients
Pharma Pioneer
3 min read
Encouraging Results on Briquilimab as Conditioning Therapy for Fanconi Anemia Patients
19 May 2024
A recent clinical trial has shown promising results for the treatment of Fanconi Anemia (FA) using a new antibody therapy named briquilimab.
Read →
Encouraging Phase 1 BEXMAB Study Results in High-Risk MDS and r/r AML Patients
Pharma Pioneer
2 min read
Encouraging Phase 1 BEXMAB Study Results in High-Risk MDS and r/r AML Patients
19 May 2024
Recent updates from the BEXMAB clinical trial indicate a positive trend in the treatment of high-risk (HR) myelodysplastic syndrome (MDS) patients who have not responded to hypomethylating agents (HMA).
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.